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Feasibility, acceptability and potential 
effectiveness of an information technology-
based, pharmacist-led intervention to 
prevent an increase in anticholinergic and 
sedative load among older community-
dwelling individuals
Helene G. van der Meer , Hans Wouters, Martina Teichert, Fabiënne Griens,  
Jugoslav Pavlovic, Lisa G. Pont and Katja Taxis
Abstract
Background: Anticholinergic/sedative medications are frequently used by older people, 
despite their negative impacts on cognitive and physical function. We explore the feasibility, 
acceptability and potential effectiveness of an innovative information technology (IT)-based 
intervention to prevent an increase in anticholinergic/sedative load in older people.
Methods: This was a prospective study in 51 Dutch community pharmacies. Pharmacists used 
an IT-based tool to identify patients aged ⩾65 years, with existing high anticholinergic/sedative 
loads (drug burden index ⩾2) and a newly initiated anticholinergic/sedative medication. We 
determined the following. Feasibility: number of eligible patients identified. Acceptability: 
pharmacists’ satisfaction with the intervention, pharmacists’ time investment and patients’ 
willingness to reduce medication use. Potential effectiveness: number of recommendations, 
rate of agreement of general practitioners (GPs) with proposed recommendations and factors 
associated with agreement. To evaluate the latter, pharmacists conducted medication reviews 
and proposed recommendations to GPs for 5–10 patients selected by the IT-based tool.
Results: We included 305 patients from 47 pharmacies. Feasibility: a mean of 17.0 (standard 
deviation, 8.8) patients were identified per pharmacy. Acceptability: 43 pharmacists (91.5%) 
were satisfied with the intervention. The median time investment per patient was 33 min 
(range 6.5–210). Of 35 patients, 30 (85.7%) were willing to reduce medication use. Potential 
effectiveness: pharmacists proposed 351 recommendations for 212 patients (69.5%). GPs 
agreed with recommendations for 108 patients (35.4%). Agreement to stop a medication was 
reached in 19.8% of recommendations for newly initiated medications (37 of 187) and for 
15.2% of recommendations for existing medications (25 of 164). Agreement was more likely 
for recommendations on codeine [odds ratio (OR) 3.30; 95% confidence interval (CI) 1.14–
9.57] or medications initiated by a specialist (OR 2.85; 95% CI 1.19–6.84) and less likely for 
pharmacies with lower level of collaboration with GPs (OR 0.15; 95% CI 0.02–0.97).
Conclusion: This innovative IT-based intervention was feasible, acceptable and potentially 
effective. In one-third of patients an increase in anticholinergic/sedative load was prevented 
within reasonable time investment.
Keywords: aged, deprescribing, drug burden index, hypnotics and sedatives, medical 
informatics, medication review, muscarinic antagonists, pharmacists
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Background
Medications with anticholinergic or sedative 
properties are of great concern in older people. 
They have a negative impact on cognitive and 
physical function and increase the risk of falls, 
dementia, hospitalization, and mortality.1–3 
Despite these risks, anticholinergic and sedative 
medications are frequently prescribed to older 
people.4,5 Interventions to reduce the anticholin-
ergic/sedative load among older individuals are 
urgently needed. One strategy that has been pro-
posed for reducing this load is a pharmacist-led 
medication review. This is ‘a structured, critical 
examination of a patient’s medicines with the 
objective of reaching an agreement with the per-
son about treatment, optimizing the impact of 
medicines, minimizing the number of medication 
related problems and reducing waste’.6 A few 
studies evaluated the effect of a pharmacist-led 
medication review on chronically used anticholin-
ergic/sedative medications. While two small 
Australian studies found positive effects,7,8 we 
found pharmacist-led medication reviews to have 
no effect on deprescribing chronically used 
anticholinergic/sedative medications in a recent 
randomized controlled trial across 15 Dutch 
community pharmacies.9
Information technology (IT)-based interventions 
targeting newly initiated medications are another 
approach that potentially may reduce anticholin-
ergic/sedative load. Since deprescribing chroni-
cally used anticholinergic/sedative medications is 
difficult, using IT to identify patients with newly 
initiated medications and performing a medica-
tion review to prevent an increase in anticholiner-
gic/sedative load may be more successful. The use 
of IT-based approaches to identify patients with 
potentially ineffective or harmful medication use 
is increasing.10 In Dutch community pharmacy 
practice, pharmacists already use IT-based drug 
therapy alerts to monitor the safety of medication 
use in electronic patient records (e.g. detecting 
drug–drug interactions, contraindications, dosing 
in patients with renal impairment).11 Thus, using 
IT to identify older individuals with newly initi-
ated anticholinergic/sedative medication is worth-
while to explore.
We built an innovative IT-based pharmacist-led 
intervention to prevent an increase in anticholin-
ergic/sedative load among older Dutch commu-
nity-dwelling individuals. In line with best 
practice for the development and evaluation of 
such a complex healthcare intervention,12 in this 
study we tested the feasibility, acceptability and 
potential effectiveness of this IT-based pharma-
cist-led intervention.
Methods
Study design and setting
The study was conducted in 51 community phar-
macies located throughout the Netherlands in 
both rural and urban areas between September 
and December 2017. At each pharmacy, one 
pharmacist participated in the study. All partici-
pating pharmacists were enrolled in the national 
2-year post-graduate programme to become a 
pharmacist specialized in community pharmacy. 
Participation in this study was part of their spe-
cialization training. Pharmaceutical care is well 
established in the Netherlands. This includes 
patient counselling for newly initiated medica-
tions, drug–drug interaction monitoring, and per-
forming medication reviews. Pharmacies operate 
a pharmacy information system with a complete 
electronic medication history of their patients, as 
each individual patient is registered with a single 
pharmacy.13 Furthermore, Dutch pharmacists 
routinely collaborate with the general practition-
ers (GPs) in the area. This includes routine con-
tact (phone or face-to-face meetings) to discuss 
individual patients and regular pharmacotherapy 
audit meetings.14 The Medical Ethical Committee 
of the University Medical Centre of Groningen 
confirmed that the study did not fall under the 
scope of the Medical Research Involving Human 
Subjects Act.
IT-based tool to identify eligible patients
Each pharmacist ran an online report module 
containing an algorithm based on the patient 
inclusion criteria (described below) in their phar-
macy information system to obtain a list of eligi-
ble patients. The module was developed by the 
Dutch Foundation for Pharmaceutical Statistics 
(SFK). The SFK has access to anonymous phar-
macy dispensing data from the pharmacy infor-
mation system of more than 95% of the Dutch 
community pharmacies; they collect these data to 
analyze national drug utilization and to provide 
pharmaceutical services.15
Eligible patients were aged ⩾65 years and 
received a newly prescribed potentially inappro-
priate anticholinergic/sedative medication in the 
past month. A newly prescribed medication was 
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defined as a medication, or a medication with a 
similar action (World Health Organisation 
Anatomical Therapeutical Chemical (ATC) 
code level 3 or 4)16 dispensed for the first time in 
a 12-month period. We screened for those newly 
prescribed anticholinergic/sedative medications 
that were known to be potentially inappropriate 
in older people, including benzodiazepines, blad-
der antimuscarinics, tricyclic antidepressants, 
opioids, classic antihistamines, antipsychotics, 
second-generation antidepressants and a few car-
diovascular medications. For these medications 
evidence-based guidance on prescribing in older 
people was available.17,18 Furthermore, patients 
needed to have a total cumulative anticholiner-
gic/sedative load above a predefined threshold 
value of 2, according to the drug burden index 
(DBI). The DBI is a measure of total cumulative 





 where, D = daily dose and δ 
= the minimum recommended daily dose.19 The 
recommended daily dose was determined accord-
ing to Dutch Pharmacotherapeutic reference 
sources.20,21 All medications with potential 
anticholinergic/sedative properties were included 
in the calculation. As there is no consensus inter-
nationally regarding which medications are con-
sidered to have anticholinergic properties,22 we 
derived a medication list based on the anticholin-
ergic medication classification by Duran and col-
leagues.23 We also included all medications with 
reported mild or strong anticholinergic/sedative 
properties and side effects in Dutch 
Pharmacotherapeutic reference sources in the 
DBI calculation.20,21 Topical preparations, ‘as 
needed’ medications and medications which 
lacked a specified dosing regimen in the elec-
tronic dispensing records were excluded from the 
DBI calculation. As the DBI per medication 
ranges between 0 and 1, depending on the daily 
dose, our chosen DBI threshold suggests that the 
patient is prescribed at least 3–4 anticholinergic/
sedative medications. In a previous study we 
found a frail older patient population using about 
3–4 anticholinergic/sedative medications being at 
risk of medication related harm and in need of 
medication optimization.9
IT-based pharmacist-led intervention
The intervention consisted of five steps. First, the 
pharmacist obtained a list of eligible patients as 
described above. For each patient identified with 
the algorithm, age, sex, DBI, medication profile 
and medication history were displayed to the 
pharmacist. Medications that contributed to the 
patients’ DBI, as well as newly initiated medica-
tions along with their date of prescription were 
highlighted. Second, from the list of displayed 
patients, pharmacists selected 5–10 patients 
whom they wished to include in this study. Third, 
the pharmacists evaluated the medication use, 
both newly initiated and existing medications, 
and drafted recommendations to reduce the 
anticholinergic/sedative load for each of the 
selected patients. For this evaluation we provided 
pharmacists an evidence-based guidance docu-
ment outlining information on rational prescrib-
ing for those anticholinergic/sedative medications 
that are known to be potentially inappropriate in 
older people, including all newly initiated medi-
cations we screened for. Information in the docu-
ment was based on recent Dutch guidelines and 
also included recommendations on nonpharma-
ceutical options.17 Fourth, pharmacists discussed 
recommendations with the GP and if needed, 
medical specialists. Pharmacists could choose 
their preferred communication method with the 
GP, but we advised a face-to-face meeting. 
Pharmacist and GP agreed who would discuss 
recommendations for medication changes with 
the patient, which would be the last step of the 
intervention.
Data collection
Data were collected by various methods. Data on 
the pharmacists, participating pharmacies, 
patients identified with the algorithm, patients 
selected for medication review, time taken for 
each step in the process and the medication 
review changes proposed were collected via an 
online questionnaire completed by the participat-
ing pharmacists. We checked for consistency and 
completeness of data reported by the pharmacists 
and based on this we excluded four pharmacists 
from the analysis.
For each selected patient, the pharmacists 
reported age, sex, reasons for selection and details 
of recommendations proposed to the GP. The 
latter were reported per medication and included 
type of recommendation (stop/substitute/start 
medication or change dose, checking indication 
for use, monitoring lab values or giving other 
advice), type of prescriber (GP or medical spe-
cialist), communication method with GP to dis-
cuss recommendations (face-to-face, phone, fax/
Therapeutic Advances in Drug Safety 10
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email or none), whether agreement on the recom-
mendation was reached and if so, who would 
communicate the recommendations to the 
patient. If pharmacists had no recommendations 
for selected patients, they were asked to provide 
the reasons for this.
The online questionnaire also included struc-
tured questions regarding the acceptability of the 
intervention. Structured questions on a 3-point 
Likert-scale were used to assess if pharmacists 
were satisfied with the intervention, if they found 
it meaningful, if it was considered practical, clear 
and educational. In addition, the pharmacists 
were asked if they would like to continue using 
the intervention in the future following comple-
tion of the study.
Data on all medications dispensed between June 
2017 and December 2017 for patients who were 
selected by the pharmacists were provided by 
SFK. The pharmacists authorized SFK to pro-
vide these data. For each patient the medications 
used on the dispensing date of the newly initiated 
medication were identified from the dataset and 
used for the analysis.
We aimed at conducting a structured telephone 
interview with 1–2 patients per pharmacy to 
explore the patients’ perspective on reducing their 
medication use. Each pharmacist asked his/her 
patients included in this study whether they were 
willing to participate in a telephone interview. 
Patients who gave verbal consent to the pharma-
cist received information about the telephone 
interview and an informed consent form. Only 
patients who signed an written informed consent 
form were interviewed. Each patient interview 
lasted about 10 min.
Feasibility
We assessed the number of potentially eligible 
patients identified with the IT-based tool per 
pharmacy and the number of falsely identified 
patients. False identification occurred if the cal-
culated DBI by the module was ⩾2, while in fact 
the real DBI was <2. This happened due to two 
problems. First, we detected an error in the online 
report module, which appeared if the pharmacist 
ran another algorithm within the online report 
module. The SFK solved the error within the first 
month of data collection, but until this time 
for these pharmacies the online report module 
did not only include currently used chronic 
medication in the DBI calculation, but also some 
anticholinergic/sedative medications that were 
already stopped. Second, the dispensing data on 
which the DBI was calculated could include 
pseudo double medication records. These were 
records of the same ATC code (level 5), strength 
and daily dose as another record within one 
patient with overlapping treatment dates. Pseudo 
double medication records were a result of early 
medication dispenses, for example, a patient had 
not yet finished a medication package, but a new 
package was already dispensed. We reduced all 
pseudo double medication records to single med-
ication records. The DBI was recalculated by 
hand after adjustment of the medication data and 
compared with the DBI calculated by the mod-
ule. All demographic characteristics and descrip-
tion of medication use were based on the adjusted 
dataset.
Acceptability
Pharmacist and patient acceptability of the inter-
vention was assessed. Pharmacists’ acceptability 
was assessed by asking the pharmacists whether 
they found the IT-based intervention meaningful, 
practical, clear, and educational. We also assessed 
their willingness to use the intervention in the 
future. Pharmacists were also asked to report the 
mean time needed per intervention step per patient.
For the patient perspective on reducing medica-
tion use, we determined the number of patients 
interviewed who expressed a desire to reduce 
their medication use, who were willing to reduce 
medication use if the GP would advise this and 
who were not willing to reduce their medication 
use even if the GP would advise this.
Potential effectiveness
Potential effectiveness was assessed in two ways. 
First, the number of recommendations proposed 
by the pharmacist and rate of agreement of GP 
with proposed recommendations was determined. 
We categorized recommendations into medica-
tion changes (stopping, substituting and starting 
a medication or dosage change) and medication 
monitoring (checking indication for use, monitor-
ing lab values or giving other advice). We also cat-
egorized recommendations for all medications, 
newly initiated and existing medications. Number 
of recommendations and rate of agreement was 
assessed per patient and type of recommendation. 
Number of patients without recommendations 
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and reasons why were counted and the number of 
recommendations per ATC level 2 and type of 
communication to the patient was assessed. 
Agreement was only counted as such if there was 
a discussion between pharmacist and GP or spe-
cialist. If the prescriber did not respond to the 
pharmacist’s recommendation, for example, if 
recommendation was sent via email or fax, this 
was counted as no agreement.
Secondly, we assessed whether patient character-
istics, type of medication, type of communication 
between pharmacist and GP, type of initiating 
prescriber and level of pharmacotherapy audit 
meeting with GPs were associated with agree-
ment of the GP with pharmacists’ recommenda-
tions. Pharmacotherapy audit meetings were 
nationally classified into four categories: no struc-
tured meetings (level 1), regular meetings without 
concrete agreements (level 2), regular meetings 
with concrete agreements (level 3) and regular 
meetings with evaluating concrete agreements 
(level 4).24 Agreements focused on the prescrib-
ing and dispensing of medications.
Statistical analysis
Descriptive statistics of all data were derived with 
IBM SPSS Statistics version 25. Factors associated 
with agreement were analyzed with logistic mixed 
effects models in MLwiN version 3. Random 
effects on the level of pharmacy and patient were 
applied. A univariate analysis on all variables was 
applied first. Variables with a univariate p-value 
< 0.1 were included in the multivariate analysis. 
A p-value <0.05 was considered significant.
Results
Study population
In total, 47 pharmacists from 47 community 
pharmacies were included in the study. Overall, 
305 patients were selected with a median of 6 
patients (range 3–10) per pharmacy selected for 
medication review. The demographic characteris-
tics of pharmacists, pharmacies and patients are 
shown in Table 1.
Feasibility
On average, 17.0 [standard deviation (SD) 8.8.0, 
range 3–32] patients per pharmacy were identi-
fied with the IT-based tool. With the calculation 
of the DBI by hand, we found that 13 selected 
patients (4.3%) had a real DBI <2. These patients 
were included due to the error we found in the 
online report module (n = 11) and pseudo dou-
ble medication records (n = 2). In addition, we 
detected pseudo double medication records for 
85 patients (27.9%), but these patients had a DBI 
⩾2 even after removing the double medication 
records. Without adjusting these pseudo double 
medication records to single records, the mean 
DBI of patients selected in this study would have 
been 4.2 (SD 2.0) versus 3.6 (SD 1.3) after 
adjustment.
Acceptability
A large majority of pharmacists (n = 43, 91.5%) 
were satisfied with the intervention (17 com-
pletely, 26 partly), 41 pharmacists (87.2%) found 
it meaningful (19 completely, 22 partly), 41 phar-
macists (87.2%) found it practical (16 com-
pletely, 25 partly), 46 pharmacists (97.9%) found 
it clear (34 completely, 12 partly) and 44 pharma-
cists (93.6%) found it educational (30 com-
pletely, 14 partly). Almost three-quarters of 
pharmacists (n = 33, 70.2%) wanted to keep 
using the intervention in the future.
The median time investment per patient was 
33 min (range 6.5–210). Most time was needed 
for medication evaluation and drafting of recom-
mendations (median 15 min, range 8–120), then 
for discussion of recommendations with the GP 
(median 10, range 5–60), for patient selection a 
median of 5 min was needed (range 2–60) and 
the least time was needed to identify patients with 
the IT-based tool (median 2 min, range 1–25).
Telephone interviews were conducted with 35 
patients (10.7%). One in five patients (n = 8, 
22.9%) reported that they wished to stop one or 
more medications or would stop on GP’s advice 
(n = 22, 62.9%). There were five patients (14.3%) 
who did not want to stop any medication, even if 
advised by the GP.
Potential effectiveness
Recommendations were proposed for 212 patients 
(69.5%), a mean of 1.7 (SD 0.9) per patient. 
Recommendations included medication changes 
(169 patients), medication monitoring (24 
patients) or both (19 patients). Overall, the GP 
agreed with pharmacists’ recommendations in 108 
patients (35.4%) and with recommendations to 
change medications in 97 patients (31.8%).
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Table 1. Demographic characteristics pharmacists and patients.
Characteristic Outcome
Pharmacists n = 47
Age, mean (±SD) 28.3 (2.3)
Sex (% female) 68.1
Working experience, mean years (±SD) 2.0 (1.0)
Working hours per week, median hours (range) 40.0 (24–45)
Pharmacies n = 47
Pharmacists FTE, mean (±SD) 2.3 (1.0)
Number of patients per pharmacy, n pharmacies per category (%)  
 <8000 3 (6.4)
 8000–10,000 11 (23.4)
 10,000–12,000 13 (27.7)
 12,000–14,000 11 (23.4)
 >14,000 9 (19.1)
Percentage of patients aged 65+ per pharmacy, n pharmacies per category (%)  
 <20% 11 (23.4)
 20–50% 24 (51.1)
 >50% 10 (21.3)
 Unknown 2 (4.3)
Number of collaborating GPs per pharmacy, mean (±SD) 12.1 (6.3)
Level of pharmacotherapy audit meetings with GPs, n pharmacies per category 
(%)
 
 Level 1: no structured meetings 0 (0.0)
 Level 2: regular meetings without concrete agreements 2 (4.3)
 Level 3: regular meetings with concrete agreements 30 (63.8)
 Level 4: regular meetings with evaluating concrete agreements 13 (27.7)
 None 2 (4.3)
Patients n = 305
Age, mean (±SD) 76.5 (8.0)
Sex (% female) 64.0
DBI value at identification, mean (±SD) 3.6 (1.3)
Number of anticholinergic/sedative medications used, mean (±SD) 5.8 (2.1)
HG van der Meer, H Wouters et al.
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Most recommendations were proposed for opi-
oids (ATC N02A, 16.8%), such as oxycodone 
and tramadol (respectively 40.7% and 42.4%), 
antidepressants (ATC N06A, 13.1%), such as 
amitriptyline (52.2%), anxiolytics (ATC N05B, 
10.3%), such as oxazepam (58.3%), and seda-
tives (ATC N05C, 9.7%), such as temazepam 
(67.6%). A detailed overview of all recommenda-
tions proposed on medication grouped by ATC 
level 2 can be found in additional file 1.
For 93 patients (30.5%) no recommendations 
were proposed. Reasons for not proposing an 
intervention were that no medication optimiza-
tion was possible, for example, the medication 
being for short term use or patient was already on 
tapering scheme (62 patients), the pharmacist 
knew beforehand that either patient or GP would 
not accept any medication recommendation (15 
patients), medication recommendations were dif-
ficult as medication was of a specialist nature (9 
patients) or due to other reasons, for example, 
patient had died (6 patients). For one patient the 
pharmacist did not report the reason for not pro-
posing a recommendation.
In total 351 recommendations were proposed, of 
which 148 (48.5%) were agreed with by the GP. 
For 13 of 351 recommendations (4.3%) the med-
ical specialist was contacted. Stopping a medica-
tion or substitution by a safer alternative were the 
most commonly proposed recommendations, 
respectively 41.3 and 32.5% of the total recom-
mendations. The rate of agreement for stopping 
Characteristic Outcome
Patients n = 305
Number of medications used, mean (±SD) 9.2 (3.3)
Reasons for patient selection for medication review, n per category (%)*  
 Newly initiated medication 142 (46.6)
 Risk factors (high age, high DBI, risk medication) 159 (52.1)
 Good collaboration with GP 98 (32.1)
 Other/no specific reason 88 (28.9)
Top 5 newly initiated anticholinergic/sedative medications, n patients (%)  
 Oxycodone 51 (16.7)
 Codeine 43 (14.1)
 Tramadol 38 (12.5)
 Temazepam 26 (8.5)
 Amitriptyline 25 (8.2)
Top 5 used medications per ATC level 1, n patients (%)  
 Cardiovascular system 285 (93.4)
 Alimentary tract and metabolism 274 (90.0)
 Nervous system 260 (85.2)
 Blood and blood-forming organs 164 (53.8)
 Respiratory system 83 (27.5)
*Multiple reasons per patient could be selected. A total of 172 patients were selected for one reason, 95 for two reasons, 
38 for >2 reasons.
ATC, Anatomical Therapeutical Chemical; DBI, drug burden index; FTE, fulltime equivalent; GP, general practitioner; SD, 
standard deviation.
Table 1. (Continued)
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or substituting a medication was higher for newly 
initiated medications (57.8% and 35.3% agree-
ment) than for existing medications (30.9% and 
24.1% agreement). Agreement to stop a medica-
tion was reached in 17.7% of recommendations 
(62 of 351), in 19.8% of recommendations for 
newly initiated medications (37 of 187) and in 
15.2% of recommendations for existing medica-
tions (25 of 164), Table 2.
Of the 148 recommendations with agreement, 
discussion with the patient was done by the GP (n 
= 54, 36.5%), pharmacist (n = 46, 31.1%) or 
someone else (n = 9, 6.1%). In some cases, there 
was no communication with the patient as he/she 
was not reachable by phone (n = 7, 4.7%) or no 
discussion was needed (for example, lab-value 
check; n = 15, 10.1%). For 17 recommendations 
(11.5%) the pharmacists did not report who con-
tacted the patient.
GP agreement with proposed recommendations 
was more likely for recommendations on cough 
and cold preparations (codeine; odds ratio (OR) 
3.30; 95% confidence interval (CI) 1.14–9.57) or 
medication initiated by a medical specialist (OR 
2.85; 95% CI 1.19–6.84). Furthermore, a less 
established working collaboration between phar-
macist and GP’s resulted in less agreement with 
recommendations compared with well-estab-




The innovative IT-based pharmacist-led inter-
vention targeting newly initiated anticholinergic/
sedative medications was feasible, acceptable and 
potentially effective. Pharmacists were able to 
identify a considerable number of older patients 
in need of medication optimization with the 
IT-based tool. Acceptability of the intervention 
was high both among pharmacists and patients. 
The potential effectiveness of the intervention 
appears high with one or more recommendations 
being proposed for over two-thirds of patients 
and agreement of GP with pharmacists’ recom-
mendations for one-third of all patients. 
Table 2. Type of recommendations by pharmacist and rate of agreement by general practitioner.*
Recommendation Total (n = 351) Newly initiated medications 
(n = 187)
Existing medications  
(n = 164)
 Proposed
n (% of total 
proposed)
Agreed
n (% of 
proposed)
Proposed
n (% of 
total)
Agreed
n (% of 
proposed)
Proposed
n (% of 
total)
Agreed
n (% of 
proposed)
 Medication changes
Stop 145 (41.3) 62 (42.8) 64 (34.2) 37 (57.8) 81 (49.4) 25 (30.9)
Substitute 114 (32.5) 37 (32.5) 85 (45.5) 30 (35.3) 29 (17.7) 7 (24.1)
Dose adjustment 32 (9.1) 15 (46.9) 14 (7.5) 5 (35.7) 18 (11.0) 10 (55.6)
Start 9 (2.6) 5 (55.6) 0 (0) – 9 (5.5) 5 (55.6)
Subtotal 300 (85.5) 119 (39.7) 163 (87.2) 72 (44.2) 137 (83.5) 47 (34.3)
 Medication monitoring
Check lab values 13 (3.7) 12 (92.3) 0 (0) – 13 (7.9) 12 (92.3)
Additional information on 
medication use (e.g. advice 
or check indication)
38 (10.8) 17 (44.7) 24 (12.8) 11 (45.8) 14 (8.5) 6 (42.9)
Subtotal 51 (14.5) 29 (56.9) 24 (12.8) 11 (45.8) 27 (16.5) 18 (66.7)
 Total 351 (100) 148 (42.2) 187 (100) 83 (44.4) 164 (100) 65 (39.6)
* for 13 of 351 recommendations (4.3%) a medical specialist was contacted.
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Table 3. Factors associated with GP agreement with recommended medication changes.
Factor Univariate Multivariate
 OR (95% CI) p-value OR (95% CI) p-value
Patient characteristics
Age 0.98 (0.95–1.01) 0.264 NA NA
Sex 0.67 (0.40–1.14) 0.142 NA NA
DBI 0.99 (0.82–1.19) 0.885 NA NA
Number of medications 1.01 (0.94–1.09) 0.844 NA NA
Type of medication
Newly initiated medication 1.75 (1.02–2.99) 0.042* 1.47 (0.84–2.58) 0.182
Drugs for acid related disorders 
(ATC code A02)
1.07 (0.39–2.97) 0.898 NA NA
Urologicals (ATC code G04) 0.86 (0.28–2.57) 0.794 NA NA
Analgesics (ATC code N02) 1.60 (0.85–3.00) 0.142 NA NA
Psycholeptic (ATC code N05) 0.52 (0.29–0.93) 0.027* 0.58 (0.32–1.07) 0.082
Psychoanaleptic (ATC code N06) 0.55 (0.26–1.17) 0.119 NA NA
Cough and cold preparations 
(ATC code R05)
4.71 (1.64–13.50) 0.004* 3.30 (1.14–9.59) 0.028*
Type of communication between pharmacist and GP
Face-to-face 2.10 (0.58–7.60) 0.262 NA NA
Telephone 1.41 (0.39–5.05) 0.613 NA NA
Fax/email 1.43 (0.37–5.55) 0.617 NA NA
None Ref Ref NA NA
Initiating prescriber
Medical specialist 2.44 (1.03–5.79) 0.042* 2.85 (1.19–6.84) 0.019*
GP Ref Ref Ref Ref
Pharmacotherapy audit meeting pharmacist/GPs
None to level 2a 0.13 (0.02–0.82) 0.030* 0.15 (0.02–0.97) 0.047*
Level 3b 1.10 (0.55–2.19) 0.809 NA NA
Level 4c Ref Ref Ref Ref
*Statistically significant.
ano (structured) meetings (level 1) or regular meetings without concrete agreements (level 2).
bregular meetings with concrete agreements (level 3).
cregular meetings with concrete agreements and evaluation (level 4).
Variables with a univariate p-value <0.1 were included in the multivariate analysis.
ATC, Anatomical Therapeutical Chemical; CI, confidence interval; DBI, drug burden index; GP, general practitioner; NA, not 
applicable, not included in the multivariate analysis; OR, odds ratio; Ref, reference.
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Agreement was more likely for recommendations 
on codeine use, for medications initiated by a 
medical specialist, and when pharmacist and GP 
had a well-established working collaboration.
Comparison with other studies
The fragile older population with a high anticho-
linergic/sedative load included in this study was 
comparable with the population selected in our 
previous randomized controlled trial on pharma-
cist-led medication review in terms of age, sex, 
DBI and medication use.9 While the previous 
study found that pharmacist-led medication review 
was not effective in reducing anticholinergic/seda-
tive load associated with chronic medication, our 
new approach targeting newly initiated anticholin-
ergic/sedative medications appears more success-
ful, especially for newly initiated medications 
including anxiolytics, hypnotics and antidepres-
sants. While our approach is innovative in the 
pharmacy setting, our results are comparable with 
a study in the general practice setting, which found 
that newly initiated benzodiazepines and tricyclic 
antidepressants, were more likely to be successfully 
reduced by GPs than long-term used hypnotics.25 
GP agreement with pharmacists’ recommenda-
tions in our study was comparable with others. In 
line with these studies, agreement seemed higher 
when GP and pharmacist had a well-established 
working collaboration.26
The GP was more likely to agree with recommen-
dations for medications with unknown or ques-
tionable efficacy and a high side effect profile, 
such as codeine.27 We found that agreement was 
higher for medications initiated by a medical spe-
cialist compared with GP. This was surprising as 
previous literature found that medical specialists 
in general are less likely to agree with pharmacist 
recommendations compared with primary care 
physicians.28 However, most recommendations in 
our study focused on psychotropic medication 
and contacting a medical specialist for these med-
ications might be preferable.
Strengths and limitations
We developed and evaluated an innovative inter-
vention performed in a relatively large homoge-
nous group of motivated, early-career pharmacists 
who had access to the full medication records for 
their patients and who were trained in pharma-
ceutical patient care. The evaluation conducted 
was robust, following accepted guidance for the 
development and evaluation of complex health 
care interventions and included feasibility, accept-
ability and potential effectiveness in a large num-
ber of pharmacists and patients.12 This evaluation 
provides valuable information for further devel-
opment and testing of the intervention. The inter-
vention was designed for the convenience of the 
pharmacist and pharmacists could adapt it to fit 
his or her practice in the real-world setting. 
Analyzing the impact of the intervention, we 
identified the number of recommendations and 
classified those in a meaningful way, distinguish-
ing between medication changes and medication 
monitoring.
Some limitations need to be taken into considera-
tion when interpreting our results. First, due to 
the nature of our study it was not possible to per-
form a follow-up meeting. We therefore do not 
know whether all planned medication changes 
were implemented. We report on the agreement 
of the GP with pharmacists’ recommendations, 
which may overestimate actual implemented 
medication changes. Also, it was outside the 
scope of our study to explore to what extent phar-
macist or GP communicated recommendations 
with the patient. Second, we do not know whether 
all steps of the intervention were followed in the 
proposed order, for example, some patients could 
have been contacted before discussion with the 
GP. However, this was a result of the real-world 
nature of the intervention and allowing some flex-
ibility in the order of steps is likely to make a strat-
egy more pragmatic in clinical practice. Third, 
using dispensed medication records has disad-
vantages, such as pseudo double medication 
records which resulted in a small number of false 
positive identification of patients with pseudo 
double medication records with the same ATC 
level 5 medications. There could have also been 
patients with pseudo double medication records 
with different ATC codes, for example, patients 
who switched to another medication with similar 
effects. Fourth, wide CIs suggest that our data 
sample was not large enough to draw strong con-
clusions about the factors associated with GP 
agreement with recommended medication 
changes. But we believe that our findings are a 
basis for further refinement of the intervention. 
Finally, this project was part of the pharmacists’ 
post-graduate training and all pharmacists should 
have been able to perform the intervention. 
However, we had to exclude four pharmacists as 
data provided from these pharmacies was incon-
sistent. We think that this is a reflection of 
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real-world practice, in which practicalities, for 
example, building renovations, changing IT sys-
tem, sickness, holidays, lack of personnel, but 
perhaps also lack of motivation may affect the 
performance of interventions. Furthermore, there 
might be a difference in motivation of using the 
IT-based tool between the young pharmacists in 
our study compared with more experienced phar-
macists in practice.
Conclusions and implications for practice and 
further research
The pharmacist-led IT-based intervention as per-
formed in this study, appears feasible, acceptable 
and potentially effective. Pharmacists needed on 
average about half an hour to perform the inter-
vention and in one out of three patients the GP 
agreed with pharmacists’ recommendations to 
change medication. Therefore, when extrapolat-
ing, about 1.5 h was needed to prevent an increase 
in anticholinergic/sedative load in one patient. 
Our results suggest some refinements of the inter-
vention should be considered prior to upscaling. 
Our study used the algorithm retrospectively to 
identify patients over the past month who could 
be considered for a medication review. In line 
with the current use of IT-based drug therapy 
alerts in Dutch pharmacy practice, the algorithm 
should be fully integrated in the pharmacy infor-
mation system. This way it will operate prospec-
tively with the system deploying an alert for a 
newly initiated anticholinergic/sedative medica-
tion that would increase the patient’s total 
anticholinergic/sedative load above the specific 
threshold at the time the prescription is presented 
for initial supply. Further therapeutic advice for 
reducing the load should be directly displayed 
alongside the alert. This way, the pharmacist is 
able to propose and discuss recommendations 
with the GP prior to dispensing the medication. 
These refinements will likely increase the rate of 
implementation of recommendations, as the 
medication change is being implemented before 
the patient has commenced treatment with the 
newly prescribed medication. Secondly, as no 
consensus-based list of anticholinergic/sedative 
medication is available,29 we included a broad 
range of medications with mild and strong 
anticholinergic/sedative properties or reported 
side effects. Most recommendations in our study 
were proposed for medications with strong 
anticholinergic/sedative properties, such as psy-
chotropic and bladder antimuscarinics, only a few 
recommendations were proposed for medications 
with mild or unknown anticholinergic/sedative 
properties, like cardiovascular medication. We 
suggest a refinement of our list, including only 
medications with known anticholinergic/sedative 
properties and frequently reported anticholiner-
gic/sedative side effects, this may reduce alert 
fatigue.30 Furthermore, while we used the DBI to 
calculate the anticholinergic/sedative load, other 
tools have been developed, among those, one that 
shows promising results.31,32 Finally while the fea-
sibility, acceptability and potential effectiveness 
of the intervention appears high, the cost-effec-
tiveness and implementation of medication rec-
ommendations and long-term medication 
changes in combination with relevant patient out-
comes, like geriatric outcomes (e.g. fall risk, frailty 
and cognitive function) and adverse events (e.g. 
drug-related hospital admission)33 should be eval-
uated in a real-world randomized controlled trial 
in community pharmacies preferably with high 
level collaboration with GPs.
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